retatrutide vs. tirzepatide
In-depth analysis of molecular mechanisms, receptor binding affinities, hepatic lipid metabolism profiles, and clinical trial outcomes between triple and dual incretin agonism.
retatrutide
Advanced rational peptide engineered to simultaneously activate GLP-1, GIP, and glucagon receptors. Accelerates hepatic mitochondrial beta-oxidation and lipid mobilization.
tirzepatide
The reference dual agonist with pharmacological bias toward the GIP receptor. Enhances glucose-dependent insulinotropic signaling and provides sustained incretin-mediated satiety.
Comparative data from landmark clinical trials (NEJM).
Mechanism of Action: Triple vs. Dual Agonism
Retatrutide
Retatrutide (LY3437943) represents the cutting edge of rational peptide engineering by uniting agonism across three crucial metabolic receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). Activating GCGR introduces an entirely new biological vector: direct stimulation of hepatic fatty acid beta-oxidation and increased basal thermogenic energy expenditure. Simultaneously, synchronized GIP and GLP-1 signaling protects against glucagon-induced glycemic elevation while driving potent hypothalamic satiety.
Tirzepatide
Tirzepatide (LY3298176) set the benchmark in incretin therapeutics as the first approved dual GIP/GLP-1 receptor agonist. Its molecular structure displays a deliberate pharmacological bias toward the GIP receptor, optimizing glucose-dependent insulin secretion and improving white adipose tissue metabolic flexibility. Unlike Retatrutide, Tirzepatide exhibits no measurable activity at the glucagon receptor (GCGR), focusing its action on delaying gastric emptying, peripheral insulin sensitization, and incretin-driven appetite modulation.
Clinical Trial Benchmarks (NEJM Reference Data)
Retatrutide Clinical Efficacy
In the Phase 2 trial published in The New England Journal of Medicine (Rosenstock et al., 2023; 389:514-526), Retatrutide demonstrated up to a 24.2% mean body weight reduction (-26.2 kg) at 48 weeks in the 12 mg cohort. The trajectory of adipose tissue reduction showed no plateau at the end of 48 weeks, indicating unprecedented metabolic potency.
Tirzepatide Clinical Efficacy
In the pivotal SURMOUNT-1 Phase 3 trial published in The New England Journal of Medicine (Jastreboff et al., 2022; 387:205-216), Tirzepatide achieved a 20.9% mean body weight reduction (-23.6 kg) at 72 weeks with the 15 mg dose. This firmly demonstrated superior efficacy over single GLP-1 receptor agonists (such as Semaglutide 2.4 mg at ~15% reduction).
Hepatic Fat Clearance: Steatosis & MASH
One of Retatrutide’s most groundbreaking distinctions is its impact on metabolic dysfunction-associated steatohepatitis (MASH / MAFLD). Driven by direct hepatic GCGR agonism, Phase 2 MRI data revealed that over 80% of subjects treated with 8 mg and 12 mg achieved complete normalization of liver fat (<5% hepatic fat content) at 48 weeks, showing an average relative liver fat reduction of up to 86%. While Tirzepatide also provides meaningful hepatic fat clearance (40-50%), Retatrutide’s glucagon component accelerates intrahepatic lipid clearance at an unmatched rate.
Pharmacological and analytical specifications.
| PARAMETER | RETATRUTIDE (LY3437943) | TIRZEPATIDE (LY3298176) |
|---|---|---|
| Agonist Class | Triple Agonist (GLP-1R / GIPR / GCGR) | Dual Agonist (GIPR / GLP-1R) |
| Target Receptors | GLP-1, GIP, Glucagon (GCGR) | GIP, GLP-1 |
| In-Vitro Binding Affinity (Human EC50) | GIPR: 0.019 nM | GLP-1R: 0.77 nM | GCGR: 5.79 nM | GIPR: 0.024 nM | GLP-1R: 0.24 nM | GCGR: >1000 nM (Inactivo) |
| Hepatic Mechanism & Thermogenesis | Accelerated lipid beta-oxidation + thermogenesis via GCGR | Peripheral lipolysis buffering mediated by GIP/GLP-1 |
| Weight Reduction Benchmark (Clinical Trials) | -24.2% at 48 weeks (Phase 2 NEJM, 12 mg) | -20.9% at 72 weeks (SURMOUNT-1 NEJM, 15 mg) |
| Hepatic Fat Clearance (Steatosis) | Up to -86% relative reduction (80%+ normalization) | -40% to -50% relative reduction |
| Plasma Elimination Half-Life (t1/2) | ~6 days (144 hours) | ~5 days (120 hours) |
| Peptide Sequence Length | 39 amino acids (C20 diacid modified backbone) | 39 amino acids (C20 diacid modified backbone) |
| HPLC / MS Purity Standard | ≥ 99.0% (Liofilizado analítico verificado) | ≥ 99.4% (Liofilizado analítico verificado) |
| Reconstitution Vehicle | Sterile Bacteriostatic Water (0.9% Benzyl Alcohol) | Sterile Bacteriostatic Water (0.9% Benzyl Alcohol) |
| Storage (Lyophilized Powder) | -20°C (24 meses de estabilidad) | -20°C (24 meses de estabilidad) |
| Storage (Reconstituted Solution) | 2°C – 8°C (hasta 28 días protegido de luz) | 2°C – 8°C (hasta 28 días protegido de luz) |
| Availability & Dispatch | In stock in Spain · Express 24-72h EU shipping (no customs) | In stock in Spain · Express 24-72h EU shipping (no customs) |
| Legal Classification | Exclusively for in-vitro / laboratory research use only | Exclusively for in-vitro / laboratory research use only |
ready to order your compound?
All peptides are supplied in vacuum-sealed lyophilized vials with >99% HPLC purity, certified by independent Mass Spectrometry. Dispatched directly from Spain with zero customs delays across Europe.
retatrutide
Lyophilized vials with verified HPLC purity ≥ 99.0%.
tirzepatide
Lyophilized 10mg and 20mg vials with verified HPLC purity ≥ 99.4%.
Frequently asked questions about Retatrutide vs. Tirzepatide.
Molecular differences, receptor binding profiles, clinical trial benchmarks, reconstitution guidelines, and legal status for laboratory research across Europe.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon (GCGR) receptors in a single unified molecule. Tirzepatide is a dual agonist targeting only GIP and GLP-1. The addition of glucagon receptor agonism in Retatrutide stimulates direct hepatic lipid beta-oxidation and thermogenic energy expenditure, whereas Tirzepatide operates primarily through incretin-mediated glycemic control and appetite suppression.
In peer-reviewed trials published in The New England Journal of Medicine, Retatrutide demonstrated up to a 24.2% mean body weight reduction at 48 weeks (Phase 2, 12 mg dose). Tirzepatide achieved a 20.9% mean weight reduction at 72 weeks in SURMOUNT-1 (Phase 3, 15 mg dose). Retatrutide showed both a higher peak percentage and a steeper rate of reduction without reaching a plateau by week 48.
Hepatic glucagon receptor activation accelerates mitochondrial fatty acid oxidation and suppresses de novo lipogenesis. In Phase 2 trials, Retatrutide yielded up to an 86% relative reduction in intrahepatic fat at 48 weeks, normalizing liver fat in over 80% of evaluable subjects. Tirzepatide produces a significant 40-50% reduction, but Retatrutide demonstrates superior direct hepatic lipid clearance.
Retatrutide exhibits balanced potency: EC50 of 0.019 nM at human GIPR, 0.77 nM at GLP-1R, and 5.79 nM at the glucagon receptor (GCGR). Tirzepatide displays potent affinity at GIPR (0.024 nM) and GLP-1R (0.24 nM), but zero measurable activity at GCGR (EC50 > 1000 nM).
Both peptides are supplied as sterile lyophilized powders. They must be reconstituted with sterile Bacteriostatic Water (0.9% Benzyl Alcohol), allowing the diluent to trickle slowly down the inner vial wall without shaking to prevent peptide shear stress. Lyophilized vials should be stored at -20°C (up to 24 months stability). Once reconstituted, maintain at 2°C–8°C shielded from UV light, remaining stable for up to 28 days.
Yes, purchasing and possessing Retatrutide and Tirzepatide is completely legal in Spain and throughout the European Union when intended exclusively for scientific research, analytical laboratory testing, and in-vitro experiments. They are not approved for human consumption, clinical use, or medical diagnosis.
Every batch of Retatrutide and Tirzepatide supplied by IberiaLabs is verified via third-party High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). We guarantee ≥ 99.0% purity, zero endotoxins, and residual moisture below 0.5%. The lot-specific Certificate of Analysis (CoA) is verifiable online and via the QR code on every vial label.
All orders are packaged in cleanroom conditions and dispatched directly from our EU Schengen facility. There are zero customs inspections, delays, or import duties across all EU member states. Delivery takes 24–72 business hours within Spain and 48–72 hours across other EU countries with express real-time tracking.